伏立康唑与米卡芬净在儿童恶性血液病深部真菌感染中的应用

Analysis of deep fungal infection treated with voriconazole and micafungin in children with malignant hematological diseases

目的:观察伏立康唑与米卡芬净对儿童恶性血液病化疗后骨髓抑制期深部真菌感染的临床疗效。方法:选取我院儿科恶性血液病化疗后骨髓抑制期患儿,临床诊断肺部侵袭性真菌感染(IPFI)病例23例,随机分为2组,分别给予伏立康唑与米卡芬净治疗,比较2组的治疗有效率、抗真菌治疗总费用和不良反应发生率。结果:2组在有效率上无显著差异,而在痊愈率上,伏立康唑组稍优于米卡芬净组(P<0.05);在抗真菌治疗总费用上,米卡芬净组较伏立康唑组具有一定优势,P<0.05;2组在不良反应发生率上差异无显著性,均无严重不良反应发生。结论:伏立康唑与米卡芬净对儿童恶性血液病深部真菌感染均具有良好的疗效及安全性。

OBJECTIVE To study the effect of voriconazole and micafungin on deep fungal infection in children with malignant hematological diseases at the rnyelosuppression stage after chemotherapy. METHODS Twenty-three patients with malig nant hematological diseases clinical diagnosed invasive fungal pulmonary infection （IPFI） at the myelosuppression stage after chemotherapy,were randomly divided into two groups, treated with voriconazole and micafungin, respectively. The effect, expense and side effects of these two medications were compared. RESULTS There was no significant difference in the effective rates between two groups （P〉0. 05）. However, the cure rate of the voriconazole group was higher than the micafungin group （P〈0. 05）. The cost-effect ratio showed that micafungin was a better cost-effective alternative than voriconazole （P〈0. 05）. The side effects of two medications had no significant difference （P〉0. 05）,and no any severe side effect was observed. CONCLUSION Either voriconazole or micafungin is effective and safe for deep fungal infection in children with malignant hematological diseases.